GlobeNewswire Inc | Jan 5, 2021 08:00AM EST

January 05, 2021

LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equilliums chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 11, 2021 at 6:00 am EST.

A webcast of the presentation will be available under the Investors section of the Companys website at https://ir.equilliumbio.com/ for 30 days.

About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.For more information, visitwww.equilliumbio.com.

Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com

Media ContactKatherine Carlyle SmithSenior Account AssociateCanale Communications+1-805-907-2497 katherine.smith@canalecomm.com